CD Bioparticles offers aptamer-drug coupling targeted drug delivery systems. With our many years of experience in the field of aptamer-targeted drug delivery and our advanced technical equipment, we can provide you with the basis for your experimental research in the field of targeted drug delivery by our core technologies in aptamer and drug coupling design.
Novel nucleic acid aptamers have been reported and have attracted the interest of many scientists. Due to the simplicity of chemical modifications and off-the-shelf molecular engineering, scientists have developed newly designed aptamers with various therapeutic approaches, aptamer-drug coupling (ApDC), from chemotherapy to phototherapy, gene therapy, and vaccines, ApDC has shown synergistic therapeutic effects in cancer treatment. Active targeting therapy utilizes the ability of the targeting element to specifically recognize diseased tissue.
Aptamer-drug couples combine a selection of less cytotoxic drugs with the aptamer, so ApDC can selectively target and kill disease cells, including cancer cells while reducing side effects. Aptamer-drug couples (ApDC) are a promising targeted drug delivery system where the aptamer can be directly linked to the drug to form nanoscale aptamer-drug conjugates that target the drug directly to the tumour site, reducing toxicity and improving the efficacy of chemotherapy.
Fig. 1 Schematic of aptamer-drug conjugates (ApDCs) as targeted Chemotherapeutics (Yoon S, et al., 2017)
CD Bioparticles provides services for the study of aptamer-drug conjugate targeted drug delivery systems. Currently, targeted therapies are at the forefront of modern medical research into numerous clinical diseases. The nucleic acid aptamer acts as a recognition ligand, targeting the site of disease and/or directing the delivery of a therapeutic agent that regulates the biological function of the target biomarker.
We provide research services for the following, including but not limited to, the following, which will be tailored to your experimental protocol.
CD Bioparticles is already experienced in the field of aptamer-drug conjugation targeted drug delivery systems and our scientists are confident that we can provide you with a quality one-stop aptamer-related service to facilitate the development of research in the area of targeted drug delivery. If you are interested in our services, please do not hesitate to contact us for more details and we look forward to hearing from you.